Roles of anoikis in hepatocellular carcinoma: mechanisms and therapeutic potential
- PMID: 39885089
- DOI: 10.1007/s12032-025-02612-9
Roles of anoikis in hepatocellular carcinoma: mechanisms and therapeutic potential
Abstract
Hepatocellular carcinoma (HCC), the most common primary liver cancer, is a highly aggressive malignancy with limited viable therapeutic options. For early HCC, resection surgery is currently the most effective treatment. However, in advanced stages, resection alone does not sufficiently address the disease, so finding a method with a better prognosis is necessary. Anoikis, known as matrix detachment-induced apoptosis or detachment-induced cell death, is crucial for tissue development and homeostasis. Cancer cells develop means to evade anoikis, e.g. anoikis resistance, thereby allowing for cells to survive under anchorage-independent conditions. HCC cells often acquire resistance to anoikis, allowing them to survive after detaching from the extracellular matrix and contributing to tumor spread. This review discusses the mechanisms of anoikis in HCC, exploring the potential of drug-induced anoikis and targeting anoikis resistance as promising therapeutic strategies for treating HCC, analyzing the value of anoikis in the immune of HCC, and propose potential pathways in oncotherapy, which can provide background knowledge for subsequent related research.
Keywords: Anoikis; Anoikis resistance; Hepatocellular carcinoma; Immune microenvironment; Prognostic signature; Therapy.
© 2025. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interests: The authors declare no competing interests. Ethical approval: Not applicable. Consent to participate: Not applicable. Consent for publication: Not applicable.
Similar articles
-
Pharmacologically inducing anoikis offers novel therapeutic opportunities in hepatocellular carcinoma.Biomed Pharmacother. 2024 Jul;176:116878. doi: 10.1016/j.biopha.2024.116878. Epub 2024 Jun 5. Biomed Pharmacother. 2024. PMID: 38843588 Review.
-
Peroxisome proliferator-activated receptor gamma inhibition prevents adhesion to the extracellular matrix and induces anoikis in hepatocellular carcinoma cells.Cancer Res. 2005 Mar 15;65(6):2251-9. doi: 10.1158/0008-5472.CAN-04-3037. Cancer Res. 2005. PMID: 15781638
-
QSOX1 promotes mitochondrial apoptosis of hepatocellular carcinoma cells during anchorage-independent growth by inhibiting lipid synthesis.Biochem Biophys Res Commun. 2020 Nov 5;532(2):258-264. doi: 10.1016/j.bbrc.2020.08.043. Epub 2020 Aug 28. Biochem Biophys Res Commun. 2020. PMID: 32863002
-
Integrative analysis of multi-omics data identified PLG as key gene related to Anoikis resistance and immune phenotypes in hepatocellular carcinoma.J Transl Med. 2024 Dec 4;22(1):1104. doi: 10.1186/s12967-024-05858-5. J Transl Med. 2024. PMID: 39633373 Free PMC article.
-
Targeting anoikis resistance as a strategy for cancer therapy.Drug Resist Updat. 2024 Jul;75:101099. doi: 10.1016/j.drup.2024.101099. Epub 2024 Jun 1. Drug Resist Updat. 2024. PMID: 38850692 Review.
References
-
- Bruix J, Sherman M, American Association for the Study of Liver Diseases. Management of hepatocellular carcinoma: an update. Hepatology. 2011;53:1020–2.
-
- Cheng A-L, Qin S, Ikeda M, Galle PR, Ducreux M, Kim T-Y, et al. Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma. J Hepatol. 2022;76:862–73.
Publication types
MeSH terms
Grants and funding
- KYCX23_3617 and SJCX23_2028/the Postgraduate Research and Practice Innovation Program of Jiangsu Province
- 82373034 and 82203716/the National Natural Science Foundation of China
- LJRC20181 and YZCXTD201801/the "13th Five-Year Plan" Science and Education Strong Health Project Innovation Team of Yangzhou
- DTRA202214/the Provincial-Level Discipline Leader of the NJPH
- YJCHZ-2021-08/the Cross-Cooperation Special Projects of the NJPH
- GDXZ-08-19/the Beiing iGanDan Foundation
- 2024-3-02/Yangzhou Basic Research Program (Joint Special Project)
- K2023002/Construction and Clinical Application of Innovative Perioperative Management System for Minimally Invasive Surgery of Hepatic Portal Hypertension in Hepatitis B-related Liver Cirrhosis
LinkOut - more resources
Full Text Sources
Medical